Clinical Trials for Idiopathic Pulmonary Fibrosis (IPF): Type V Collagen Oral Solution

ImmuneWorks has completed enrollment of idiopathic pulmonary fibrosis (IPF) patients in our Phase I clinical trial, and we are in the process of completing the trial at some of the most respected academic research centers across the United States. This clinical trial is designed to test ImmuneWorks’ oral treatment in IPF patients who have demonstrated autoimmunity to Type V collagen.

For more information about ImmuneWorks’ FDA-approved IPF clinical trial, please visit ClinicalTrials.gov.